✦ LIBER ✦

A PHASE II CLINICAL STUDY OF HIGH-DOSE CALCITRIOL PLUS DOCETAXEL AND ZOLEDRONIC ACID IN HORMONE-REFRACTORY PROSTATE CANCER (HRPC)

✍ Scribed by M. Bulbul; A. Shamseddine; J. Makarem; Z. Abdel Khalik; A. Taher; N. El-Saghir; R. Khawli; K. Hemadeh

Book ID: 118647450
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 52 KB
Volume: 5
Category: Article
ISSN: 1569-9056
DOI: 10.1016/s1569-9056(06)60294-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Docetaxel, Vinorelbine, and Zoledronic A

Docetaxel, Vinorelbine, and Zoledronic Acid as First-Line Treatment in Patients with Hormone Refractory Prostate Cancer: A Phase II Study

✍ Giuseppe Di Lorenzo; Riccardo Autorino; Sisto Perdonà; Michele De Laurentiis; Ma 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 137 KB

Docetaxel and zoledronic acid combinatio

Docetaxel and zoledronic acid combination administered in two different sequences in hormone refractory prostate cancer patients: Phase I clinical study – ZANTE

✍ G. Facchini; M. Caraglia; A. Morabito; S.G. Bruni; G. Nasti; P. Maiolino; S. Str 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 38 KB

A phase I/II dose-escalation study of ex

A phase I/II dose-escalation study of exisulind and docetaxel in patients with hormone-refractory prostate cancer

✍ Christopher W. Ryan; Walter M. Stadler; Nicholas J. Vogelzang 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 101 KB

A phase 2 study of carboplatin plus doce

A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel

✍ Robert W. Ross; Tomasz M. Beer; Susanna Jacobus; Glenn J. Bubley; Mary-Ellen Tap 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB 👁 2 views

## Abstract ## BACKGROUND. Prostate cancer is the second leading cause of cancer mortality among men in the U.S. To the authors' knowledge, there is no proven, effective, second‐line therapy for docetaxel‐refractory disease. Recent data suggest that platinum salts may be effective when combined wi

1245 Zoledronic acid and Taxotere (ZANTE

1245 Zoledronic acid and Taxotere (ZANTE) metronomic and sequential administration in patients with hormone refractory prostate cancer (HRPC) – final results of phase I study

✍ M. Caraglia; A. Morabito; M. Marra; A.M. Bochicchio; M.C. Piccirillo; R. Franco; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 49 KB

211 POSTER Results of a phase II study o

211 POSTER Results of a phase II study of picoplatin with docetaxel and prednisone in chemotherapy-naive patients with metastatic hormone refractory prostate cancer (HRPC)

✍ R. DeJager; L. Roman; N. Lopatkin; P. Karlov; H.B. Breitz; R. Earhart 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 59 KB